GO:0097158 pre-mRNA intronic pyrimidine-rich binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097158 (pre-mRNA intronic pyrimidine-rich binding) describes the molecular function of proteins that bind CU-rich intronic sequences in pre-messenger RNA.
• This binding activity is central to splice-site recognition and alternative splicing regulation, influencing isoform diversity in normal development and disease.
• Key RNA-binding proteins including PTB, hnRNP A1, hnRNP K, TIA-1, MBNL1 and HuR recognize pyrimidine-rich intronic elements to modulate exon inclusion or skipping.
• The WT1 +/-KTS isoform switch is a classic example where an intronic pyrimidine-rich sequence and its antagonism by HuR control a critical developmental decision.
• Dysregulation of pyrimidine-rich intronic binding contributes to cancer, neurological disorders and splicing-related pathologies, making it a therapeutic target.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of these RNA-protein interactions in disease-relevant cell types.
Description
Pre-mRNA intronic pyrimidine-rich binding (GO:0097158) is a molecular function defined as binding to a pyrimidine-rich (CU-rich) intronic sequence of a pre-messenger RNA. This activity is performed by a subset of RNA-binding proteins that recognize short uridine/cytosine-rich motifs within introns, often near splice sites or within intronic splicing enhancers and silencers. Because intronic pyrimidine tracts are abundant in human pre-mRNAs, proteins that bind them serve as key nodes in the combinatorial control of splicing. The functional importance of this binding activity is illustrated by the WT1 gene, where an intronic pyrimidine-rich sequence regulates the balance of +/-KTS isoforms, and the RNA-binding protein HuR antagonizes this effect. Similarly, polypyrimidine tract binding protein (PTB) and its brain-specific counterpart mediate neuron-specific splicing switches through arrays of pre-mRNA repressor sites. Other proteins such as hnRNP A1, hnRNP K, TIA-1 and MBNL1 also engage pyrimidine-rich or pyrimidine-embedded motifs to proofread 3' splice site recognition, activate alternative exons, or regulate alternative splicing. For researchers, GO:0097158 provides a precise annotation for interrogating how sequence-specific RNA-protein interactions shape transcriptomes. Understanding this function is essential for dissecting splicing dysregulation in cancer, neurodegeneration and developmental disorders, and for designing CRISPR-based models that test causality of specific RNA-binding proteins and their target intronic elements.
pre-mRNA intronic pyrimidine-rich binding At A Glance
| GO ID | GO:0097158 |
|---|---|
| GO term | pre-mRNA intronic pyrimidine-rich binding |
| Ontology | molecular_function |
| Synonym | pre-messenger RNA intronic pyrimidine-rich binding |
| Definition | Binding to a pyrimidine-rich (CU-rich) intronic sequence of a pre-messenger RNA (pre-mRNA). |
| Major function | Sequence-specific recognition of CU-rich intronic elements to regulate splice-site selection and alternative splicing. |
| Representative proteins | PTB, hnRNP A1, hnRNP K, TIA-1, MBNL1, HuR |
| Related process | Pre-mRNA splicing, alternative exon inclusion/skipping, isoform switching |
| Disease relevance | Cancer, neurological disorders, developmental splicing defects |
What Is GO:0097158?
GO:0097158, pre-mRNA intronic pyrimidine-rich binding, is the molecular function of selectively binding to a pyrimidine-rich (CU-rich) intronic sequence within a pre-messenger RNA molecule. This definition captures a sequence-specific RNA-binding activity rather than a catalytic or structural role, and it is distinct from general RNA binding or from binding to pyrimidine-rich sequences outside introns.
Why Is pre-mRNA intronic pyrimidine-rich binding Important in Cell Biology?
GO:0097158 is important because pyrimidine-rich intronic elements are pervasive in human pre-mRNAs and serve as platforms for assembling splicing regulatory complexes that determine exon inclusion or skipping. Proteins that bind these elements, such as PTB, hnRNP A1, hnRNP K, TIA-1, MBNL1 and HuR, are frequently dysregulated in cancer and neurological disease, and their binding activity directly influences isoform switches with functional consequences. Studying this molecular function therefore connects RNA sequence recognition to cellular phenotypes and disease mechanisms.
• Controls alternative splicing of critical genes such as WT1, where an intronic pyrimidine-rich sequence regulates +/-KTS isoform balance.
• Mediates neuron-specific splicing switches through arrays of pre-mRNA repressor sites bound by PTB and a brain-specific PTB counterpart.
• Enables hnRNP A1 to proofread 3' splice site recognition by U2AF, ensuring splicing fidelity.
• Allows hnRNP K to act as a component of an intronic splicing enhancer complex that activates alternative exon 6A of chicken beta-tropomyosin.
• Supports MBNL1 binding to GC motifs embedded in pyrimidines to regulate alternative splicing.
• Provides a mechanistic basis for TIA-1 multi-domain RNA recognition and splicing regulation.
• Links RNA-binding protein function to cancer-associated isoform switches and tumor suppressor/oncogene activities.
• Contributes to neurological disease mechanisms through misregulated splicing of neuronal transcripts.
• Offers a target for antisense oligonucleotide and CRISPR-based splicing modulation therapies.
• Enables functional annotation of intronic variants that create or disrupt pyrimidine-rich motifs.
Molecular Mechanism of pre-mRNA intronic pyrimidine-rich binding
Recognition of CU-rich intronic elements
In simple terms: Proteins scan introns for short stretches rich in C and U letters and latch onto them.
The defining event of GO:0097158 is sequence-specific recognition of pyrimidine-rich (CU-rich) intronic sequences within pre-mRNA. This recognition is mediated by RNA-binding domains that preferentially contact uridine and cytosine bases, allowing proteins such as PTB and hnRNP A1 to discriminate pyrimidine-rich tracts from other intronic sequences. In the WT1 gene, an intronic pyrimidine-rich sequence serves as a regulatory element whose binding modulates isoform choice.
Assembly of splicing regulatory complexes
In simple terms: Once bound, these proteins recruit or block other splicing factors to decide which exons are kept.
Binding to pyrimidine-rich intronic elements nucleates the assembly of splicing regulatory complexes. hnRNP K is a component of an intronic splicing enhancer complex that activates splicing of alternative exon 6A from chicken beta-tropomyosin pre-mRNA. Conversely, PTB and its brain-specific counterpart mediate repression through arrays of pre-mRNA repressor sites, producing neuron-specific splicing switches. TIA-1, a multi-domain splicing factor, also engages RNA targets through its domains to influence splice-site selection.
Competition and antagonism at intronic elements
In simple terms: Different proteins can compete for the same pyrimidine-rich spot, and one can push the other off.
A key mechanistic feature is competition between RNA-binding proteins for overlapping or adjacent pyrimidine-rich elements. HuR antagonizes the effect of an intronic pyrimidine-rich sequence in regulating WT1 +/-KTS isoforms, demonstrating that the functional outcome depends on which protein occupies the element. Similarly, hnRNP A1 proofreads 3' splice site recognition by U2AF, illustrating how pyrimidine-rich binding can compete with or modulate core splicing factor activity.
Coupling to splice-site selection and isoform output
In simple terms: The binding decision ultimately changes which version of the mRNA is made.
The downstream consequence of GO:0097158 is altered splice-site selection and isoform output. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing, showing that pyrimidine-rich contexts can integrate additional sequence features. In ultra-short introns, unusual mechanisms including G-rich intron recognition have been proposed, highlighting context dependence of intronic binding rules. Together, these events determine whether exons are included or skipped, directly shaping the proteome.
Regulation by RNA-binding protein abundance and modification
In simple terms: How much of each protein is present, and how it is modified, changes the binding outcome.
The occupancy and functional impact of pyrimidine-rich intronic binding are modulated by the relative abundance of competing RNA-binding proteins and by their post-translational modifications. The antagonism between HuR and the intronic pyrimidine-rich sequence in WT1 regulation implies that cellular levels of HuR set the threshold for isoform switching. Neuron-specific splicing switches mediated by PTB and a brain-specific PTB counterpart further demonstrate that tissue-specific expression of RNA-binding proteins rewires pyrimidine-rich element usage.
Key Genes Involved in GO:0097158 pre-mRNA intronic pyrimidine-rich binding
The following genes encode RNA-binding proteins with demonstrated or strongly implicated roles in binding pyrimidine-rich intronic sequences and regulating pre-mRNA splicing.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTBP1 | Binds polypyrimidine tracts to repress or activate splicing | Neuron-specific splicing switches and alternative exon regulation |
| HNRNPA1 | Proofreads 3' splice site recognition by U2AF | Splicing fidelity and cancer-associated isoform changes |
| HNRNPK | Component of intronic splicing enhancer complex | Activates alternative exon 6A of beta-tropomyosin |
| TIA1 | Multi-domain splicing factor with RNA recognition | Structure, dynamics and RNA binding in splicing regulation |
| MBNL1 | Binds GC motifs embedded in pyrimidines | Regulates alternative splicing in muscle and other tissues |
| ELAVL1 (HuR) | Antagonizes intronic pyrimidine-rich sequence effects | WT1 +/-KTS isoform regulation |
| WT1 | Host gene with intronic pyrimidine-rich regulatory element | Isoform balance in development and cancer |
| U2AF1 | Core 3' splice site factor interacting with pyrimidine tracts | Target of hnRNP A1 proofreading |
| U2AF2 | Core 3' splice site factor interacting with pyrimidine tracts | Target of hnRNP A1 proofreading |
| SRSF1 | SR protein involved in splice-site selection | General splicing regulation context |
| SRSF2 | SR protein involved in splice-site selection | General splicing regulation context |
| PTBP2 | Brain-specific PTB counterpart | Neuron-specific splicing switch |
| HNRNPC | Binds pyrimidine-rich sequences | General hnRNP splicing regulation |
| HNRNPU | RNA-binding nuclear protein | General splicing and RNA processing |
| RBM39 | Splicing factor with RNA recognition motifs | Splice-site selection |
| CELF1 | CU-rich element binding protein | Alternative splicing regulation |
| KHDRBS1 | Signal transduction and RNA binding | Splicing and RNA processing |
How Is pre-mRNA intronic pyrimidine-rich binding Regulated?
The activity of pre-mRNA intronic pyrimidine-rich binding is regulated at multiple levels. Tissue-specific expression of RNA-binding proteins such as the brain-specific PTB counterpart rewires which pyrimidine-rich elements are occupied, producing neuron-specific splicing switches. Competition between proteins for the same element, as shown by HuR antagonizing an intronic pyrimidine-rich sequence in WT1 regulation, provides a second layer of control. Post-transcriptional and post-translational mechanisms that alter RNA-binding protein abundance or localization therefore tune the functional output of GO:0097158.
pre-mRNA intronic pyrimidine-rich binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| WT1 | Wilms tumor and isoform imbalance | Knockout or point-mutation of intronic pyrimidine-rich element in cell lines |
| ELAVL1 (HuR) | Cancer progression and isoform regulation | Overexpression and knockout in cancer cell lines |
| PTBP1 | Neuronal splicing switches | Neuron-like differentiation models with PTBP1 knockout |
| MBNL1 | Neuromuscular splicing misregulation | Knockout and knock-in of MBNL1 in muscle cell models |
| HNRNPA1 | Splicing fidelity defects | Point-mutation models affecting 3' splice site proofreading |
Cancer and isoform switching
Dysregulated pyrimidine-rich intronic binding can shift isoform ratios of genes with oncogenic or tumor-suppressive functions. The WT1 +/-KTS isoform switch, controlled by an intronic pyrimidine-rich sequence and antagonized by HuR, is a paradigm for how this molecular function influences cell fate and proliferation. MBNL1-mediated regulation of alternative splicing via pyrimidine-embedded motifs has also been linked to transcriptomic changes relevant to disease.
Neurological and neuromuscular disorders
Neuron-specific splicing switches mediated by PTB and a brain-specific PTB counterpart depend on arrays of pre-mRNA repressor sites, highlighting how pyrimidine-rich intronic binding shapes neuronal transcriptomes. MBNL1, which binds GC motifs embedded in pyrimidines, is a key regulator of alternative splicing in muscle and brain, and its dysfunction is associated with splicing misregulation in neuromuscular disease.
Splicing fidelity and genetic disease
hnRNP A1 proofreads 3' splice site recognition by U2AF, and perturbations in this quality-control step can lead to aberrant splicing associated with disease. Intronic variants that create or destroy pyrimidine-rich motifs may therefore alter RNA-protein interactions and contribute to splicing-related pathologies.
From pre-mRNA intronic pyrimidine-rich binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of an RNA-binding protein alter pyrimidine-rich intronic binding and isoform ratios? | CRISPR knockout cell line followed by RNA-seq and CLIP-based assays |
| Does a specific intronic pyrimidine-rich motif drive isoform switching? | Point mutation of the motif in a knock-in cell line |
| Can a disease-associated isoform be restored by modulating binding? | Knock-in of a tagged RNA-binding protein and rescue experiments |
| Which transcripts are directly bound by the protein? | Overexpression of tagged protein followed by RNA immunoprecipitation |
| Does tissue-specific expression of a PTB counterpart change splicing? | Overexpression of brain-specific PTB in non-neuronal cells |
| Can splicing enhancer complexes be reconstituted? | Knock-in of hnRNP K and reporter minigene assays |
How to Study the pre-mRNA intronic pyrimidine-rich binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CLIP / RIP-seq | Direct RNA binding sites | Mapping pyrimidine-rich intronic occupancy |
| RNA-seq | Transcriptome and isoform changes | Detecting exon inclusion/skipping after perturbation |
| Minigene reporter assay | Splicing of a defined exon | Testing intronic pyrimidine-rich element function |
| Mutagenesis | Requirement of specific motifs | Defining CU-rich element necessity |
| NMR / biophysics | RNA-protein interaction dynamics | Structural basis of TIA-1 RNA binding |
| CRISPR knockout | Loss-of-function phenotype | Causal testing of RNA-binding proteins |
| CRISPR knock-in | Tagged or mutant protein/motif | Tracking binding and isoform output |
| Overexpression | Gain-of-function effects | Testing HuR antagonism of intronic element |
RNA immunoprecipitation and CLIP-based mapping
RNA immunoprecipitation and crosslinking-immunoprecipitation (CLIP) allow direct mapping of pyrimidine-rich intronic binding sites for proteins such as PTB, hnRNP A1, hnRNP K, TIA-1, MBNL1 and HuR. These methods identify the exact intronic sequences occupied in cells and can be combined with CRISPR knockout to distinguish direct from indirect effects.
Splicing-sensitive RNA-seq and isoform quantification
RNA-seq with isoform-level quantification detects changes in exon inclusion and isoform ratios caused by altered pyrimidine-rich intronic binding. The WT1 +/-KTS isoform switch is a classic readout that can be monitored by targeted assays after perturbation of HuR or the intronic element. Neuron-specific splicing switches mediated by PTB can be similarly tracked in differentiation models.
Minigene reporters and motif mutagenesis
Minigene reporters carrying wild-type or mutated pyrimidine-rich intronic elements enable precise testing of motif function. Mutagenesis of the WT1 intronic pyrimidine-rich sequence and of beta-tropomyosin exon 6A enhancer elements has been used to define regulatory logic. These assays are compatible with CRISPR knock-in of reporter cassettes.
Structural and biophysical characterization
Structural and biophysical approaches, including NMR and binding assays, reveal how multi-domain splicing factors such as TIA-1 recognize RNA targets. Such studies complement cellular assays by defining the molecular determinants of pyrimidine-rich sequence recognition and the dynamics of RNA-protein complexes.
How CRISPR Can Be Used to Study GO:0097158 pre-mRNA intronic pyrimidine-rich binding
Knockout
CRISPR knockout of genes encoding pyrimidine-rich intronic binding proteins, such as PTBP1, HNRNPA1, HNRNPK, TIA1, MBNL1 or ELAVL1, enables loss-of-function analysis of splicing outcomes. Knockout cell lines can be profiled by RNA-seq to identify isoform changes and by CLIP to confirm loss of binding at CU-rich intronic sites.
Point Mutation
Point mutation of the intronic pyrimidine-rich sequence itself, for example in the WT1 regulatory element, allows precise testing of motif necessity without altering protein levels. CRISPR base editing or homology-directed repair can introduce single-nucleotide changes that disrupt or create CU-rich motifs, followed by isoform-specific assays.
Knock-in
Knock-in of epitope-tagged RNA-binding proteins or of reporter minigenes carrying defined intronic elements supports direct tracking of binding and splicing in a native chromatin context. Tagged knock-in of MBNL1 or HuR can be combined with CLIP to map pyrimidine-rich targets.
Overexpression
Overexpression of RNA-binding proteins such as HuR or a brain-specific PTB counterpart can reveal gain-of-function effects on pyrimidine-rich intronic binding and isoform switching. Overexpression models are particularly useful for testing antagonism between competing proteins at the same intronic element.
How EDITGENE Supports pre-mRNA intronic pyrimidine-rich binding Research
Researchers studying pre-mRNA intronic pyrimidine-rich binding-related genes often need to determine whether a candidate RNA-binding protein or intronic motif is causally involved in a splicing phenotype. EDITGENE provides CRISPR-based cell model services that enable precise perturbation of both the protein and the RNA element, supporting mechanistic and translational studies of GO:0097158.
Contact EDITGENE today to design your custom CRISPR model for pre-mRNA intronic pyrimidine-rich binding research.
Frequently Asked Questions About pre-mRNA intronic pyrimidine-rich binding
What is pre-mRNA intronic pyrimidine-rich binding?
It is the molecular function defined by GO:0097158, describing the binding of proteins to pyrimidine-rich (CU-rich) intronic sequences within pre-messenger RNA.
What genes are involved in pre-mRNA intronic pyrimidine-rich binding?
Genes encoding RNA-binding proteins such as PTBP1, HNRNPA1, HNRNPK, TIA1, MBNL1 and ELAVL1 (HuR) are involved in recognizing pyrimidine-rich intronic elements.
How does pyrimidine-rich intronic binding regulate splicing?
Bound proteins recruit or block splicing factors at nearby splice sites, thereby promoting exon inclusion or skipping and altering isoform output.
Which diseases are linked to pyrimidine-rich intronic binding?
Cancer, neurological and neuromuscular disorders have been linked to dysregulated pyrimidine-rich intronic binding and downstream isoform changes.
What is the role of HuR in WT1 isoform regulation?
HuR antagonizes the effect of an intronic pyrimidine-rich sequence in regulating WT1 +/-KTS isoforms, thereby influencing isoform balance.
How can I study pre-mRNA intronic pyrimidine-rich binding in the lab?
Common approaches include CLIP/RIP-seq, RNA-seq, minigene reporters, mutagenesis and CRISPR knockout or knock-in models.
What is the GO ID for pre-mRNA intronic pyrimidine-rich binding?
The GO ID is GO:0097158, under the molecular_function ontology.
Does PTB bind pyrimidine-rich intronic sequences?
Yes, PTB and a brain-specific PTB counterpart mediate neuron-specific splicing switches through arrays of pre-mRNA repressor sites.
How does hnRNP A1 proofread 3' splice site recognition?
hnRNP A1 proofreads 3' splice site recognition by U2AF, contributing to splicing fidelity at pyrimidine-rich regions.
Can CRISPR be used to study pyrimidine-rich intronic elements?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models enable causal testing of RNA-binding proteins and intronic motifs.
Conclusion
GO:0097158, pre-mRNA intronic pyrimidine-rich binding, defines a sequence-specific RNA-binding function that is central to splice-site selection and alternative splicing. Proteins such as PTB, hnRNP A1, hnRNP K, TIA-1, MBNL1 and HuR recognize CU-rich intronic elements to shape isoform output, with the WT1 +/-KTS switch providing a well-characterized example of functional impact. Because dysregulation of this activity is linked to cancer and neurological disease, precise CRISPR models are essential for causal dissection. EDITGENE supports this research with knockout, point-mutation, knock-in, overexpression, library screening and bioinformatics services tailored to RNA-binding protein and intronic element studies.
References
- 1. Li H et al.. 2015. HuR antagonizes the effect of an intronic pyrimidine-rich sequence in regulating WT1 +/-KTS isoforms.. RNA Biol 12(12):1364-71 PMID: 26512748
- 2. Wang I et al.. 2014. Structure, dynamics and RNA binding of the multi-domain splicing factor TIA-1.. Nucleic Acids Res 42(9):5949-66 PMID: 24682828
- 3. Ashiya M et al.. 1997. A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart.. RNA 3(9):996-1015 PMID: 9292499
- 4. Sasaki-Haraguchi N et al.. 2012. Mechanistic insights into human pre-mRNA splicing of human ultra-short introns: potential unusual mechanism identifies G-rich introns.. Biochem Biophys Res Commun 423(2):289-94 PMID: 22640740
- 6. Goers ES et al.. 2010. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing.. Nucleic Acids Res 38(7):2467-84 PMID: 20071745
- 7. Tavanez JP et al.. 2012. hnRNP A1 proofreads 3' splice site recognition by U2AF.. Mol Cell 45(3):314-29 PMID: 22325350
- 8. Expert-Bezançon A et al.. 2002. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA.. J Biol Chem 277(19):16614-23 PMID: 11867641
